Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): Implications for pathogenesis

Blood

Volumn 101, Issue 8, 2003, Pages 3181-3187

  Quintanilla Martinez, Leticia ^b   Davies Hill, Theresa ^b   Fend, Falko ^b   Calzada Wack, Julia ^b   Sorbara, Lynn ^b   Campo, Elias ^b   Jaffe, Elaine S ^b   Raffeld, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P27; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MONOCLONAL ANTIBODY; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLAST CELL; CARCINOGENESIS; CELL ASSAY; CELL GROWTH; CELL LEVEL; CELL LINE; CELL PROLIFERATION; CELL TYPE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING; CANCER STEM CELL; CELL DIVISION; CELL TRANSFORMATION; CHROMOSOME 11; CHROMOSOME 14; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; IMMUNOLOGY; MACROMOLECULE; METABOLISM; PATHOLOGY; PROTEIN BINDING; SERODIAGNOSIS;

ANTIBODIES, MONOCLONAL; CELL CYCLE PROTEINS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, MANTLE-CELL; MACROMOLECULAR SUBSTANCES; NEOPLASM PROTEINS; PRECIPITIN TESTS; PROTEIN BINDING; TRANSLOCATION, GENETIC; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEINS;

EID: 0038281327     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0263     Document Type: Article

References (47)

1. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
2. 1 phase progression: cycling on cue. Cell. 1994;79:551-553.
3. 1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
4. Sherr CJ. D-type cyclins. Trends Biol Sci. 1995;20:187-190.
5. 1-phase progression. Genes Dev. 1999;13:1501-1512.
6. 1 phase of the human cell cycle. Science. 1992;257:1689-1694.
7. 1-S phase protein kinase. Science. 1992;257:1958-1961.
8. Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996;272:877-880.
9. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67-74.
10. KIP-1, a cyclin-dependent kinase inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
11. 1 phase arrest mediated by an inhibitor (p27KIP1) of cyclin-dependent kinase 4 activation. Cell. 1994;79:487-496.
12. KIP-1. Genes Dev. 1997;11:1464-1478.
13. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 1995;86:841-854.
14. Vlach JS, Amati H, Amati B. Phosphorylation dependent degradation of the cyclin-dependent kinase inhibitor p27kip1. EMBO J. 1997;16:5334-5344.
15. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(kip1) ubiquitination and degradation is regulated by the SCF (Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999;9:661-664.
16. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193-199.
17. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol.1999;1:207-214.
18. Amati B, Vlach J. Kip1 meets SKP2: new links in cell cycle control. Nat Cell Biol. 1999;1:E91-93.
19. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1 a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153:175-182.
20. KIP-1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995;55:1211-1214.
21. KIP-1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995;55:1206-1210.
22. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor p27/KIP-1 in human malignancies. Cancer Res. 1995;55:2266-2269.
23. KIP-1, to regions involved in human cancer. Cancer Res. 1995;55:1199-1205.
24. Campo E, Raffeld M, Jaffe E. Mantle cell lymphoma. Semin Hematol. 1999;36:115-127.
25. Lovec H, Grzeschiczek A, Kowalski MB, Möröy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487-3495.
26. Lovec H, Sewing A, Lucibello FC, Müller R, Möröy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene. 1994;9:323-326.
27. Quelie DE, Ashmun RA, Shurleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993;7:1559-1571.
28. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993;8:3447-3457.
29. Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas: functional studies in a cell line (Granta 519). Leukemia. 1997;11:64-72.
30. Saltman DL, Cachia PG, Dewar AE, et al. Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. Blood. 1988;72:2026-2030.
31. Vaandrager JW, Kluin P, Schuuring E. The t(11; 14)(q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. Blood. 1996;89:349-350.
32. Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997;89:272-280.
33. Cai K, Dynlacht BD. Activity and nature of p21WAF1 complexes during the cell cycle. Proc Natl Acad Sci U S A. 1998;95:12254-12259.
34. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A. 1998;95:1091-1096.
35. O'Brien V, Grindlay GJ, Campo S. Cell transformation by the E5/E8 protein of bovine papillomavirus type 4. P27Kip1, elevated through increased protein synthesis, is sequestered by cyclin D1-CDK4 complexes. J Biol Chem. 2001;276:33861-33868.
36. Cheng M, Olivier P, Diehl JA, et al. The p21Cip1 and p27 Kip1 CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999;18:1571-1583.
37. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321-5333.
38. Perez-Roger I, Kim S-H, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1. EMBO J. 1999;18:5310-5320.
39. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619-626.
40. Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol. 2002;160:1457-1466.
41. Adamson A, Lin Z, Perez-Ordoñez B, et al. Expression of SKP2, a p27 ubiquitin ligase in malignant lymphoma: correlation with p27 and proliferation index. Blood. 2002;100:2950-2956.
42. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakidis TR, Roberts JM. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature. 2001;413:323-327.
43. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A. 1997;94:6380-6385.
44. Hernandez L, Fest Th, Cazarola M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351-3359.
45. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, et al. Anomalous high p27/Kip1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. P27/Kip1-cyclin D3 colocalization in tumor cells. Blood. 1999;94:765-772.
46. Won KA, Reed SI. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 1996;15:4182-4193.
47. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996;10:1979-1990.